(ERNA) Ernexa Therapeutics Inc. Business Model Canvas Research

Ernexa Therapeutics Inc. needs academic oncology partners to de-risk ERNA-101 by pairing its cytokine-based cell therapy with translational labs, tumor models, and early biomarker work. In FY2025, the U.S. National Cancer Institute funded about $7.2 billion in cancer research, showing how central academic networks are to solid-tumor validation.

• Model solid-tumor biology
• Test cytokine therapy signals
• Speed translational readouts

Ernexa Therapeutics Inc. needs a regulatory advisor network because preclinical cell therapy programs face a 30-day FDA IND review clock, and first-in-class engineered cell products often need early alignment on IND-enabling studies and CMC (chemistry, manufacturing, and controls) plans. Advisors help reduce costly rework by shaping tox, potency, and release data before the filing.

• 30-day IND review timing
• Early CMC planning
• IND-enabling study design
• Better fit for first-in-class cells

Ernexa Therapeutics Inc. must run IND-enabling studies to build the safety, potency, and manufacturing data needed for its future FDA filing. These GLP and CMC steps come before any human trial, because regulators need proof the product is reproducible and low risk.

• Safety data for FDA review
• Potency assay validation
• Manufacturing consistency checks

Without this package, the Company cannot move into first-in-human testing.

Ernexa Therapeutics Inc. must keep filing patent coverage and expanding preclinical datasets, because those two assets drive partner interest and valuation. In biotech, patent protection typically lasts 20 years from filing, so every new dataset helps extend proof around the platform and reduce diligence risk for licensees.

• Protect the platform with patents
• Build preclinical evidence for partners
• Use data to support valuation
• Strengthen long-term strategy

Preclinical datasets are Ernexa Therapeutics Inc.'s core intangible asset: in vitro and in vivo results turn lab work into proof for partner talks and IND planning. In biotech, where roughly 90% of drug candidates fail before approval, strong data is what keeps early value from being just a story.

• Supports scientific claims and diligence
• Shapes regulatory strategy early
• Raises partner and investor confidence

Ernexa Therapeutics Inc. sits in Cambridge, Massachusetts, inside the Greater Boston life sciences hub, which has thousands of biotech and pharma firms and dense university and hospital links. That helps with hiring, partnering, and fast access to labs, talent, and research tools.

• Deep biotech talent pool
• Easy access to partners
• Strong lab and research network

Ernexa Therapeutics Inc. links 2 therapeutic markets, oncology and autoimmune disease, under one platform, so one asset base can create value in 2 large care areas. That spread lowers single-disease risk and gives Ernexa Therapeutics Inc. more room to partner each program by indication, stage, or geography.

• 2 disease areas, 1 platform
• Risk spread across markets
• More partnering options

Ernexa Therapeutics Inc. centers its platform on engineered cytokine delivery, aiming to release biologically active cytokines locally through cells instead of flooding the body with systemic exposure. That local delivery can improve targeting and may reduce toxicity, a key issue for cytokines like IL-2 and IL-12 that have shown strong activity but narrow therapeutic windows.

• Local cytokine release, not systemic dosing
• Better target control, lower off-target exposure
• Core mechanism behind the platform story

Partner diligence support is central to Ernexa Therapeutics Inc.’s customer relationships because licensing and collaboration talks depend on clear access to data, IP, and program strategy. Ernexa must package technical and regulatory evidence fast so partners can assess risk, and that speed helps move deal discussions forward.

• Share data, IP, and strategy
• Support technical diligence
• Provide regulatory detail
• Speed licensing talks

Ernexa Therapeutics Inc. needs open, data-backed updates on preclinical progress and risk, because biotech trust comes from reproducible results, not promises. With about 90% of drug candidates still failing in clinical development and timelines often running 10 to 15 years, clear disclosure helps investors judge whether each study adds real de-risking.

• Share reproducible preclinical data.

• Disclose key risks early.

• Track progress across long timelines.

Scientific conferences give Ernexa Therapeutics Inc direct access to researchers, clinicians, and partners, so they are a fast way to share early data, test the science, and build credibility. Major meetings like AACR draw over 22,000 attendees and thousands of abstracts, which makes them strong channels for validation and deal networking.

• Early data sharing
• Scientific validation
• Partner networking

Ernexa Therapeutics Inc. should use direct business development outreach to drive licensing and co-development talks, since this channel is the main route to find partners before any clinical commercialization. In biotech, early-stage deals often hinge on direct founder-to-partner contact, with upfront payments, milestones, and royalties shaped by the asset and data package.

• Direct outreach starts partnering.
• Supports licensing and collaboration.
• Most important before commercialization.

Capital providers are Ernexa Therapeutics Inc.'s core customer segment because the company is preclinical and depends on outside cash to fund R&D, manufacturing work, and FDA/regulatory prep. That makes investors and financing partners essential for both survival and future pipeline growth.

• Fund R&D and preclinical studies
• Cover manufacturing and CMC work
• Support regulatory preparation
• Keep the company funded

If Ernexa Therapeutics Inc.'s programs reach the clinic, hospitals and specialty centers become the end users because cell therapies need trained staff, controlled handling, and patient monitoring. In 2025, the FDA had cleared more than 40 cell and gene therapies, and most are delivered at specialized treatment sites, not standard outpatient offices.

• Specialized administration sites are required.
• Hospitals become the likely treatment setting.
• Centers handle real-world patient delivery.

Ernexa Therapeutics Inc. must keep spending on patent filings, freedom-to-operate reviews, and IND planning as its programs move forward. In 2025, preclinical biotech peers often spent about 20% to 35% of operating cash on IP and regulatory work, and those costs usually rise before IND submission.

• Patent defense stays on, even before trials.
• IND prep adds legal, CMC, and FDA work.
• Spend climbs as each program advances.

Ernexa Therapeutics Inc.’s G&A overhead covers management, legal, finance, and public company costs, plus Cambridge-based personnel and office overhead. These costs keep the operating platform running; in biotech, G&A often scales with headcount and SEC reporting needs more than with R&D output.

• Management and legal support
• Finance and public company costs
• Personnel and office overhead
• Operating platform support

Future product sales are only a long-term upside for Ernexa Therapeutics Inc.: ERNA-101 and ERNA-102 are still preclinical, so there is no approved-product revenue today. If either reaches approval, direct sales could become the main revenue stream, but the timing is still uncertain.

• Preclinical stage; no sales yet
• Approval needed before revenue starts
• Commercial upside is still prospective

Non-dilutive research funding can help Ernexa Therapeutics Inc. cover lab work, preclinical studies, and trial prep without issuing shares. In early biotech, grants and sponsored research often matter most because product revenue usually comes later, so this cash can extend runway and reduce dilution.

• Supports R&D before sales.
• Reduces equity dilution.
• Fits pre-revenue biotech models.